Imugene Adds Second Complete Response in Azer-Cel BTKi Cohort
Imugene ASX:IMU says its concurrent BTKi cohort in the Phase 1b azer-cel basket trial has delivered a second complete response within 24 hours.The latest update centres on azer-cel, formally azercabtagene zapreleucel, in a cohort combining the company’s off-the-shelf CAR T therapy with a Bruton Tyr…